1426 - Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Post Hoc Analyses from the SEQUOIA Study

Primary Author / Presenter(s)

Mazyar Shadman, MD, MPH

Professor
Fred Hutchinson Cancer Center
Seattle, Washington, United States

CT

Constantine S. Tam, MD, MBBS

Consultant Haematologist
Alfred Hospital and Monash University
Melbourne, Victoria, Australia
Danielle M. Brander, MD

Assistant Professor of Medicine, Division of Hematologic Malignancies & Cellular Therapy
Duke University Medical Center
Durham, North Carolina, United States
NK

Nataliya Kuptsova-Clarkson, MD

BeOne Medicines Ltd
San Carlos, California, United States
TT

Tian Tian

BeOne Medicines Ltd
San Carlos, California, United States
ML

Marcus Lefebure, PhD

BeOne Medicines Ltd
London, England, United Kingdom
SA

Stephanie Agresti, BS

BeOne Medicines Ltd
San Carlos, California, United States
JH

Jamie Hirata, PharmD

BeOne Medicines Ltd
San Carlos, California, United States
Talha Munir, MBBS, MRCP, FRCPath, PhD

Consultant Haematologist
Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom